Neuroimaging & Brain MeasuresMicrodosingPsilocybin

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study

This randomised feasibility study (n=37) evaluates psilocybin-assisted (microdoses x 6) frontal-midline theta neurofeedback (NF) to improve executive functions (EFs) in participants with psychiatric disorders. Despite no significant improvements in tasks-based EFs, the experimental group reported medium to high gains in daily EFs, indicating the potential benefits of this neuromodulation technique for enhancing daily functioning.

Authors

  • Enriquez-Geppert, S,, Lietz, M. P.
  • O'Higgins, F.

Published

Philosophical Transactions of the Royal Society B
individual Study

Abstract

Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting treatment and training responsiveness. In this pioneering study, we evaluated the feasibility and preliminary efficacy of psilocybin-assisted frontal-midline theta neurofeedback (NF), a neuromodulation technique leveraging neuroplasticity, to improve executive functions (EFs). Thirty-seven eligible participants were randomized into an experimental group (n = 18) and a passive control group (n = 19). The experimental group underwent three microdose sessions and then three psilocybin-assisted NF sessions, without requiring psychological support, demonstrating the approach’s feasibility. NF learning showed a statistical trend for increases in frontal-midline theta from session to session with a large effect size and non-significant but medium effect size dynamical changes within sessions. Placebo effects were consistent across groups, with no tasks-based EF improvements, but significant self-reported gains in daily EFs-working memory, shifting, monitoring and inhibition-showing medium and high effect sizes. The experimental group’s significant gains in their key training goals underscored the approach’s external relevance. A thorough study with regular sessions and an active control group is crucial to evaluate EFs improvement and their specificity in future. Psilocybin-enhanced NF could offer significant, lasting benefits across diagnoses, improving daily functioning.

Available with Blossom Pro

Research Summary of 'Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study'

Introduction

Executive function (EF) deficits are a transdiagnostic problem across psychiatric disorders, impairing everyday functioning and limiting recovery and treatment efficacy. The fronto-cingulo-parietal network underpins EFs, with frontal-midline (fm) theta oscillations (a 4–8 Hz EEG rhythm) implicated as a marker and mediator of top‑down control; higher fm-theta power typically relates to better EF performance. Neurofeedback (NF) trains participants to self‑regulate specific neural signals such as fm-theta and has shown medium-sized effects on components of EF, notably working memory updating, but substantial inter-individual variability and a notable proportion of 'non-responders' limit clinical translation. Impaired neuroplasticity in psychiatric populations may underlie reduced NF responsiveness, and recent preclinical and clinical evidence suggests that serotonergic psychedelics, including psilocybin, act as potent psychoplastogens via 5‑HT2A and TrkB/BDNF-related signalling.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (25)

Papers cited by this study that are also in Blossom

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

Kopra, E., Cleare, A. J., Rucker, J. et al. · Journal of Affective Disorders (2022)

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)

330 cited
Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

Towards an understanding of psychedelic-induced neuroplasticity

Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)

Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity

Glazer', J., Murray, C. H., Nusslock', R. et al. · Neuropsychopharmacology (2022)

Show all 25 references
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)

90 cited
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)

112 cited
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals

McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Natural language signatures of psilocybin microdosing

Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)

11 cited
42 cited
Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants

Holze, F., Becker, A. M., Kolaczynska, K. E. et al. · Clinical Pharmacology and Therapeutics (2022)

34 cited
Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis

Vizeli, P., Straumann, I., Holze, F. et al. · Scientific Reports (2021)

40 cited
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration

Fadiman, J., Korb, S. · Journal of Psychoactive Drugs (2019)

Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)

95 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.